相似文献
1
Delayed Hypersensitivity Reaction to OnabotulinumtoxinA.
Mov Disord Clin Pract. 2018 Mar 9;5(3):321-322. doi: 10.1002/mdc3.12575. eCollection 2018 May-Jun.
2
Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No.
Mov Disord Clin Pract. 2018 Mar 6;5(2):141-144. doi: 10.1002/mdc3.12582. eCollection 2018 Mar-Apr.
3
Episodic Ataxia Type 1 (K-channelopathy) Manifesting as Paroxysmal Nonkinesogenic Dyskinesia: Expanding the Phenotype.
Mov Disord Clin Pract. 2017 Jul 31;4(5):784-786. doi: 10.1002/mdc3.12518. eCollection 2017 Sep-Oct.
4
Imaging Evidence of Nigrostriatal Degeneration in DYT-PRKRA.
Mov Disord Clin Pract. 2020 Apr 6;7(4):472-474. doi: 10.1002/mdc3.12941. eCollection 2020 May.
5
Reversible Acute Parkinsonism and Unusual Neuroimaging Findings in Systemic Lupus Erythematosus.
Mov Disord Clin Pract. 2020 Apr 7;7(4):459-461. doi: 10.1002/mdc3.12943. eCollection 2020 May.
6
Ataxia Telangiectasia Gene Mutation in Isolated Segmental Dystonia Without Ataxia and Telangiectasia.
Mov Disord Clin Pract. 2017 Dec 3;5(1):89-91. doi: 10.1002/mdc3.12564. eCollection 2018 Jan-Feb.
7
Editorial: Looked-after children - a perspective into a more resilient future.
Child Adolesc Ment Health. 2015 Nov;20(4):181. doi: 10.1111/camh.12127.
8
Nutritional Management of Cholestasis.
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):9-12. doi: 10.1002/cld.865. eCollection 2020 Jan.
9
Novel Therapies for Managing Cholestasis.
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):95-99. doi: 10.1002/cld.886. eCollection 2020 Mar.
10
Managing the Symptoms and Complications of Cholestasis.
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):120-124. doi: 10.1002/cld.901. eCollection 2020 Mar.
引用本文的文献
1
Fluoroscopic OnabotulinumtoxinA injection for Bertolotti Syndrome in refractory back pain: A letter to the editor.
Interv Pain Med. 2024 Jan 25;3(1):100386. doi: 10.1016/j.inpm.2024.100386. eCollection 2024 Mar.
2
Therapeutic Efficacy of Botulinum Toxin in Trigeminal Neuralgia.
Cureus. 2022 Jul 14;14(7):e26856. doi: 10.7759/cureus.26856. eCollection 2022 Jul.
本文引用的文献
1
First case of anaphylaxis after botulinum toxin type A injection.
Clin Exp Dermatol. 2017 Oct;42(7):760-762. doi: 10.1111/ced.13108. Epub 2017 Jun 21.
2
Anaphylaxis--a practice parameter update 2015.
Ann Allergy Asthma Immunol. 2015 Nov;115(5):341-84. doi: 10.1016/j.anai.2015.07.019.
3
A new facial expression to botox!
Am J Emerg Med. 2014 Mar;32(3):290.e5-6. doi: 10.1016/j.ajem.2013.10.017. Epub 2013 Oct 14.
4
Clinical relevance of botulinum toxin immunogenicity.
BioDrugs. 2012 Apr 1;26(2):e1-9. doi: 10.2165/11599840-000000000-00000.
5
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
Clin Rehabil. 2009 May;23(5):394-407. doi: 10.1177/0269215508099860. Epub 2009 Apr 23.
6
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
J Am Acad Dermatol. 2005 Sep;53(3):407-15. doi: 10.1016/j.jaad.2005.06.011.
7
Fatal case of BOTOX-related anaphylaxis?
J Forensic Sci. 2005 Jan;50(1):169-72.
8
Safety of botulinum toxin type A: a systematic review and meta-analysis.
Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962.
9
Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection.
Mov Disord. 1997 Nov;12(6):1064-7. doi: 10.1002/mds.870120637.
Zotero 插件